Cargando…

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis

BACKGROUND: Proprotein convertase subtilisin / Kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents. This drug is related to improving the prognosis of patients with cardiovascular disease (CVD). The purpose of this meta-analysis was to systematically analyze the safety and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Liming, Liu, Ying, Cao, Ziting, Wang, Jun, Huo, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362201/ https://www.ncbi.nlm.nih.gov/pubmed/37484718 http://dx.doi.org/10.18502/ijph.v52i5.12707

Ejemplares similares

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
por: Jia, Xiaoming, et al.
Publicado: (2022)

PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
por: Bodapati, Adi prasad, et al.
Publicado: (2023)

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
por: Myers, Kelly D., et al.
Publicado: (2019)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
por: Wang, Xing, et al.
Publicado: (2022)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017)

PCSK9 inhibitors: Add-on therapy to reduce stroke risk
por: Earl, Grace
Publicado: (2019)

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
por: Waiz, Mohd, et al.
Publicado: (2022)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
por: Arrieta, Alejandro, et al.
Publicado: (2017)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
por: Ciccarelli, Giovanni, et al.
Publicado: (2018)

Sex-Specific Association of Endogenous PCSK9 With Memory Function in Elderly Subjects at High Cardiovascular Risk
por: Simeone, Paola G., et al.
Publicado: (2021)

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
por: Hassan, Mohamed
Publicado: (2015)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Finding inhibitors for PCSK9 using computational methods
por: Zainab, Rida, et al.
Publicado: (2021)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease
por: Igweonu-Nwakile, Emmanuelar O, et al.
Publicado: (2022)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency
por: Tarasov, Kirill, et al.
Publicado: (2014)

Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis
por: Jamialahmadi, Tannaz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rc3vjakhm264mg4e7m1jorvgpm